FORM 6 - K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 of
The Securities Exchange Act of 1934
For the month of June 2000
Commission File Number 0-29350
VASOGEN INC.
(Translation of Registrant's name into English)
2155 Dunwin Drive, Suite 10, Mississauga, Ontario, L5L 4M1
(Address of principal executive offices)
(Indicate by check mark whether the registrant files or will file annual reports
under cover Form 20-F or Form 40-F.)
Form 20-F X Form 40-F
----- -----
(Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of
1934.)
Yes No X
----- -----
This Form 6-K consists of:
A press release issued by Vasogen Inc. on June 22, 2000, entitled: "Vasogen
Announces $14 Million Bought Deal":
SIGNATURE
---------
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
VASOGEN INC.
By ___________________________________
(Name: Christopher Waddick)
(Title: Vice-President, Finance & CFO)
Date: June 26, 2000
<PAGE>
Vasogen Inc. INVESTOR CONTACT
2155 Dunwin Drive Trevor Burns
Mississauga, ON, Canada L5L 4M1 Investor Relations
tel: (905) 569-2265 fax: (905) 569-9231 tel: (905) 569-9065
http://www.vasogen.com e-mail: [email protected]
--------------------------------------------------------------------------------
FOR IMMEDIATE RELEASE
VASOGEN ANNOUNCES $14 MILLION BOUGHT DEAL
Toronto, Ontario (June 22, 2000) -- Vasogen Inc. (TSE:VAS; AMEX:MEW) today
announced that it has entered into an underwriting agreement on a "bought deal"
basis with Research Capital Corporation for the issuance and sale of 1.4 million
common shares at a price of $10.00 per share for total gross proceeds of $14
million. Closing is scheduled to take place on or about July 13, 2000.
The underwriter may, prior to June 26, 2000, increase the size of the issue by
an additional 350,000 common shares at the same price.
The Company has granted the underwriter an over-allotment option, exercisable
until closing, to purchase up to an additional 15% of the number of common
shares issued on closing on the same terms and conditions noted above. The
Company has also granted the underwriter a compensation option, exercisable for
a period of 15 months from closing, to acquire 100,000 common shares at $10.00
per share.
Net proceeds of the offering will be used to support the Company's research and
development program, ongoing operations, and business development. The Company's
cash position at closing taking into account the net proceeds of the 1.4 million
common share issue is projected to be approximately $38 million.
Vasogen is focused on developing immune modulation therapies to advance the
treatment of cardiovascular, autoimmune and related inflammatory
diseases. These therapies are designed to target fundamental
disease-causing events, providing safe, effective treatment.
Statements contained in this press release, including those pertaining to
scientific and clinical research, commercialization plans, strategic alliances,
and intellectual property protection, other than statements of historical fact,
are forward-looking statements subject to a number of uncertainties that could
cause actual results to differ materially from statements made.
"For information purposes only. The issue is not being offered to
residents of the United States of America."
